Home Companies Amgen

Amgen

    Latest
    Amgen

    Amgen Offers $167M for Cancer Collaboration Partner Nuevolution

    Drugs
    Amgen

    Amgen, Entera to Partner on Oral Drugs for Inflammatory Disease, Other...

    Nuevolution
    Amgen

    Amgen Selects Second Cancer Target in 2-Year-Old Collaboration with Nuevolution

    Amgen

    Amgen, MD Anderson Launch Two Cancer Collaborations

    Amgen and Novartis are set to commercially launch the migraine prevention treatment Aimovig™ (erenumab) in the U.S. next week—the first calcitonin gene-related peptide (CGRP) receptor inhibitor approved by the FDA.
    Amgen

    Amgen, Novartis Set to Launch Migraine Drug Aimovig Next Week after...

    Source: ©sergign/Fotolia
    Amgen

    Federal Circuit Favors Novartis’ Sandoz over Amgen in Biosimilar “Patent Dance”...

    Amgen

    Amgen, Novartis Expand Alzheimer’s Collaboration with New Trial

    Amgen

    Amgen, CytomX Launch Up-to-$1.465B+ Cancer Immunotherapy Collaboration

    Amgen

    Amgen Delaying U.S. Launch of Humira Biosimilar in Settlement with AbbVie

    Amgen

    After FDA Approval, Amgen–Allergan Cancer Biosimilar Mvasi Faces Launch, Pricing Challenges

    12Page 1 of 2
    Copyright © 2022 Genetic Engineering & Biotechnology News. All Rights Reserved.